FT: Pfizer to pay US$47.50/share (RM200/share) for Metsera, plus up to US$22.50 tied to milestones

FT: Deal may be announced Monday, pending final talks

Pfizer eyes anti-obesity market after setbacks

NEW YORK, Sept 22 — Pfizer is closing in on a potential US$7.3 billion takeover of weight-loss drug developer Metsera, the Financial Times reported yesterday, citing unidentified sources.

The US pharma firm will acquire New York City-based Metsera for US$47.50 per share in cash, with an additional US$22.50 per share contingent on the achievement of certain performance milestones, the newspaper said, adding that the announcement could come as early as today, unless deal talks fall through.

Reuters could not immediately confirm the report. Pfizer and Metsera did not immediately respond to a Reuters request for comment outside regular business hours.

Talks to acquire Metsera come just months after the biotech firm’s blockbuster Nasdaq debut, underscoring surging investor appetite for companies developing next-generation weight-loss therapies.

The US$47.50-per-share bid marks a roughly 42.5 per cent premium over Metsera’s Friday closing price of US$33.32, which pegged its market value at about US$3.5 billion, according to LSEG data.

The deal marks Pfizer’s latest bid to secure a foothold in the lucrative anti-obesity drug market, following setbacks in its own development efforts.

The company had been working on an experimental weight-loss pill, danuglipron, but abandoned the project in April after a mid-stage trial revealed poor tolerability. A once-daily extended-release version was later tested in roughly 1,400 patients, but persistent liver safety concerns further undermined the company’s ambitions.

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment company Population Health Partners, is developing injectable and oral drugs to treat obesity, based on the GLP-1 mechanism and other biological targets.

Its lead candidate, MET-097i, an injectable, showed an average weight loss of 11.3 per cent in patients during a mid-stage trial, the company said earlier this year.

Demand for weight-loss drugs is surging, with rivals Eli Lilly and Novo Nordisk intensifying their battle for market dominance.

Some experts forecast that the global weight-loss drug market could be valued at US$150 billion by the early 2030s. — Reuters